Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study

[1]  Y. N. Park,et al.  Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy , 2016, Yonsei medical journal.

[2]  P. Chow,et al.  Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials , 2016, Liver Cancer.

[3]  Korea,et al.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma , 2015, Gut and liver.

[4]  J. Seong,et al.  Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis , 2015, Cancer research and treatment : official journal of Korean Cancer Association.

[5]  Y. N. Park,et al.  Concurrent Chemoradiotherapy Shows Long-Term Survival after Conversion from Locally Advanced to Resectable Hepatocellular Carcinoma , 2014, Yonsei medical journal.

[6]  Carlo La Vecchia,et al.  Hepatocellular carcinoma epidemiology. , 2014, Best practice & research. Clinical gastroenterology.

[7]  W. Koom,et al.  Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma , 2013, Journal of radiation research.

[8]  J. Seong,et al.  Radiotherapeutic Strategies in the Management of Hepatocellular Carcinoma , 2011, Oncology.

[9]  T. Goto,et al.  Hepatocellular carcinoma with extrahepatic metastasis , 2011, Cancer.

[10]  T. Vogl,et al.  Portal vein thrombosis and arterioportal shunts: effects on tumor response after chemoembolization of hepatocellular carcinoma. , 2011, World journal of gastroenterology.

[11]  S. Ahn,et al.  Early α‐fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[12]  A. Ardiri,et al.  Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer. , 2010, Drug news & perspectives.

[13]  H. Imamura,et al.  AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC , 2010, Journal of Gastroenterology.

[14]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[15]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[16]  J. Seong,et al.  Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis , 2008, Cancer.

[17]  K. Kaneko,et al.  Preoperative predictors of vascular invasion in hepatocellular carcinoma. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  J. Weintraub,et al.  Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. , 2007, Journal of vascular and interventional radiology : JVIR.

[19]  C. Georgiades,et al.  Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. , 2005, Journal of vascular and interventional radiology : JVIR.

[20]  Josepa Ribes,et al.  Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.

[21]  M. Sata,et al.  Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis , 2002, Cancer.

[22]  T. Asahara,et al.  Hepatic arterial infusion of 5‐fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein , 2002, Journal of surgical oncology.

[23]  H. Toyoda,et al.  The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. , 1995, Oncology.

[24]  R. Yamada,et al.  Hepatic artery embolization in 120 patients with unresectable hepatoma. , 1983, Radiology.

[25]  이익재,et al.  Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma , 2013 .

[26]  이익재,et al.  Radiotherapeutic strategies in the management of hepatocellular carcinoma , 2011 .

[27]  J. Seong,et al.  Radiotherapeutic parameters predictive of liver complications induced by liver tumor radiotherapy. , 2009, International journal of radiation oncology, biology, physics.

[28]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[29]  H. Pitt,et al.  Chemoembolization in patients at high risk: results and complications. , 2006, Journal of vascular and interventional radiology : JVIR.

[30]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.